NINDS rt-PA
1995
Tissue Plasminogen Activator for Acute Ischemic Stroke
In 624 patients with acute ischaemic stroke within 3 h, intravenous alteplase 0.9 mg/kg improved functional outcome at 3 months versus placebo.
Result
Efficacy: Favourable functional outcome at 90 daysOR 1.7 (95% CI 1.2-2.6) · P = 0.008
Below 1 favours placebo, above 1 favours intravenous alteplase 0.9 mg/kg.
Also reported: Symptomatic ICH 6.4% vs 0.6%.
- Subtopic
- IV thrombolysis
- Design
- Double-blind RCT, NIH
- Relevance
- Practice-defining: a trial the guidelines cite as evidence.
- Cited in
- AHA/ASA 2026 Stroke
- Source
- The NINDS rt-PA Stroke Study Group. N Engl J Med. 1995;333(24):1581-1587.doi 10.1056/NEJM199512143332401
Discussion & critique
Founding trial of IV thrombolysis; ICH risk shaped patient selection and quality metrics for two decades.